Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics as Adjuvant in Moderate to Severe Persistent Asthma
NCT06657066Phase 3Completed
- Sponsor
- King Edward Medical University
- Start
- Dec 2021
- Primary completion
- Apr 2022
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of saccharomyces boulardii in asthma (2 arms), sponsored by King Edward Medical University. Primary endpoint: Frequency of asthma exacerbations at 3 months. Started Dec 2021; status: completed.
02
Drugs
saccharomyces boulardii
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06657066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06657066.